Surface engineered nanoliposomal platform for selective lymphatic uptake of asenapine maleate: In vitro and in vivo studies

Managuli, Renuka S.; Wang, Julie; Faruqu, Farid N.; Pandey, Anand; Jain, Sanyog; Al‐Jamal, Khuloud T.; Mutalik, Srinivas

doi:10.1016/j.msec.2019.110620

Cited by 37 publications

(12 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanoliposomes were prepared by the thin‐film hydration method [32] by dissolving soy lecithin and cholesterol (9:1 w/w in mg) in 10 mL of chloroform in a round bottom flask. Chloroform was evaporated to form a thin film using a rotary flash evaporator (Buchi Rotavapor) at 45°C.…”

Section: Methodsmentioning

confidence: 99%

Box–Behnken design aided optimization and validation of developed reverse phase HPLC analytical method for simultaneous quantification of dolutegravir sodium and lamivudine co‐loaded in nano‐liposomes

Mutalik

Mullick

Pandey

et al. 2021

J of Separation Science

Self Cite

View full text Add to dashboard Cite

A stability‐indicating reversed‐phase high‐performance liquid chromatography method for simultaneous estimation of dolutegravir sodium and lamivudine encapsulated in the nanoliposomal formulation was developed. The chromatographic parameters namely, organic phase ratio, flow rate, and sample injection volume were selected as independent factors and were optimized by multivariate Box–Behnken design. Responses analyzed were retention time, peak area, and resolution. The optimized chromatographic method with Hypersil BDS C8 CN column as stationary phase and methanol and acetonitrile mixture and acidified Milli‐Q water (pH 2.8, adjusted with 0.02% v/v orthophosphoric acid) as the mobile phase in an isocratic elution mode was validated according to parameters of International Conference on Harmonization Q1(R2) guidelines. The validated reversed‐phase high‐performance liquid chromatography method exhibited specificity for both dolutegravir sodium and lamivudine in the presence of degradation products as well as the liposomal matrix. This method was effectively utilized to determine the amount of drug entrapped and drug loading efficiency of dolutegravir sodium and lamivudine in a nano‐liposomal formulation.

show abstract

Section: Methodsmentioning

confidence: 99%

Box–Behnken design aided optimization and validation of developed reverse phase HPLC analytical method for simultaneous quantification of dolutegravir sodium and lamivudine co‐loaded in nano‐liposomes

Mutalik

Mullick

Pandey

et al. 2021

J of Separation Science

Self Cite

View full text Add to dashboard Cite

show abstract

“…Peptidic ligand RGD recognizes α 5 β 1 integrin overexpressed on M cells 136 , 145 , 146 but undergoes gradual degradation in the GIT, thus calling for synthesis of more stable non-peptidic analogues such as RGD peptidomimetic (RGDp) 147 . RGDp-decorated poly (lactic -co- glycolic acid) (PLGA) nanoparticles was prepared to testify the efficacy of non-peptidic ligands 148 .…”

Section: Cell Pathwaymentioning

confidence: 99%

An update on oral drug delivery via intestinal lymphatic transport

Zi-chen

Lü

et al. 2021

Acta Pharmaceutica Sinica B

113

View full text Add to dashboard Cite

Orally administered drug entities have to survive the harsh gastrointestinal environment, penetrate the enteric epithelia and circumvent hepatic metabolism before reaching the systemic circulation. Whereas the gastrointestinal stability can be well maintained by taking proper measures, hepatic metabolism presents as a formidable barrier to drugs suffering from first-pass metabolism. The pharmaceutical academia and industries are seeking alternative pathways for drug transport to circumvent problems associated with the portal pathway. Intestinal lymphatic transport is emerging as a promising pathway to this end. In this review, we intend to provide an updated overview on the rationale, strategies, factors and applications involved in intestinal lymphatic transport. There are mainly two pathways for peroral lymphatic transport—the chylomicron and the microfold cell pathways. The underlying mechanisms are being unraveled gradually and nowadays witness increasing research input and applications.

show abstract

“…Liposomes are spherical nanostructures made up of an outer phospholipid bilayer and an inner hydrophilic core. Liposomes have the unique ability to encapsulate both lipophilic and hydrophilic drugs and are biocompatible and biodegradable. − There are many reports available on the liposomal formulations of various antiviral drugs for the treatment of viral infections. As an example, indinavir-loaded immunoliposomes were developed for the treatment of HIV for enhanced delivery of the drug to lymphoid organs.…”

Section: Therapeutic Nanoconstructs In Covid-19 Therapymentioning

confidence: 99%

Architectured Therapeutic and Diagnostic Nanoplatforms for Combating SARS-CoV-2: Role of Inorganic, Organic, and Radioactive Materials

Pandey

Nikam

Mutalik

et al. 2020

ACS Biomater. Sci. Eng.

Self Cite

View full text Add to dashboard Cite

Although extensive research is being done to combat SARS-CoV-2, we are yet far away from a robust conclusion or strategy. With an increased amount of vaccine research, nanotechnology has found its way into vaccine technology. Researchers have explored the use of various nanostructures for delivering the vaccines for enhanced efficacy. Apart from acting as delivery platforms, multiple studies have shown the application of inorganic nanoparticles in suppressing the growth as well as transmission of the virus. The present review gives a detailed description of various inorganic nanomaterials which are being explored for combating SARS-CoV-2 along with their role in suppressing the transmission of the virus either through air or by contact with inanimate surfaces. The review further discusses the use of nanoparticles for development of an antiviral coating that may decrease adhesion of SARS-CoV-2. A separate section has been included describing the role of nanostructures in biosensing and diagnosis of SARS-CoV-2. The role of nanotechnology in providing an alternative therapeutic platform along with the role of radionuclides in SARS-CoV-2 has been described briefly. Based on ongoing research and commercialization of this nanoplatform for a viral disease, the nanomaterials show the potential in therapy, biosensing, and diagnosis of SARS-CoV-2.

show abstract

Surface engineered nanoliposomal platform for selective lymphatic uptake of asenapine maleate: In vitro and in vivo studies

Cited by 37 publications

References 31 publications

Box–Behnken design aided optimization and validation of developed reverse phase HPLC analytical method for simultaneous quantification of dolutegravir sodium and lamivudine co‐loaded in nano‐liposomes

Box–Behnken design aided optimization and validation of developed reverse phase HPLC analytical method for simultaneous quantification of dolutegravir sodium and lamivudine co‐loaded in nano‐liposomes

An update on oral drug delivery via intestinal lymphatic transport

Architectured Therapeutic and Diagnostic Nanoplatforms for Combating SARS-CoV-2: Role of Inorganic, Organic, and Radioactive Materials

Contact Info

Product

Resources

About